Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

Abstract: A all-solid-state battery includes a first battery cell in which a negative electrode current collector including a negative electrode lead portion, a first negative electrode layer, a first solid electrolyte layer and a first positive electrode layer are sequentially stacked, a second battery cell in which a second positive electrode layer, a second solid electrolyte layer and a second negative electrode layer are sequentially stacked, a third battery cell in which a third negative electrode layer, a third solid electrolyte layer, a third positive electrode layer, and a positive electrode current collector including a positive electrode lead portion are sequentially stacked, a first connection electrode connected to the first positive electrode layer and the second negative electrode layer, and a second connection electrode connected to the second positive electrode layer and the third negative electrode layer. The first to third battery cells are connected in series.

Abstract: An all-solid-state battery includes: a columnar battery cell, having a central axis extending in a first direction, in which a positive electrode active material, a positive electrode support, a solid electrolyte layer, a negative active material, and a negative electrode support are sequentially stacked from a center of the battery cell; a plurality of connection members disposed on both surfaces of the battery cell in a third direction; a negative electrode terminal connected to the connection members; and a positive electrode terminal connected to the connection members. The all-solid-state battery includes a groove portion disposed in the third direction of the battery cell and disposed in the first direction, and includes at least two battery cells.

Abstract: The present disclosure relates generally to modulators of human glycolate oxidase enzyme and methods of use and manufacture thereof.

Abstract: Provided herein are compounds, and pharmaceutically acceptable salts thereof, useful as KRAS G12D and/or KRAS G12C inhibitors, methods of making and using the same (singly or in combination with additional agents), and pharmaceutical compositions thereof.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: A light emitting display device and driving method are disclosed. A light emitting display device includes a display panel including RGBW sub-pixels; a driver configured to drive the display panel; and a timing controller configured to control the driver, wherein W peak luminance derived by the W sub-pixels is higher than a sum of RGB peak luminances derived by the RGB sub-pixels when the display panel displays an image.

Abstract: An array antenna includes an antenna substrate including a first ceramic member, an insertion member and a second ceramic member sequentially stacked, antenna pattern portions arranged on the antenna substrate in an array form, and shielding vias disposed inside the antenna substrate and extending in a thickness direction of the antenna substrate. The shielding vias are disposed in thickness areas of the antenna substrate corresponding to the antenna pattern portions.

Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: A haptic device according to one embodiment can comprise: a database unit for storing acoustic information or receiving the acoustic information from an external device; a control unit for converting the acoustic information into an electrical signal according to a predetermined pattern; a driving unit for generating a motion signal on the basis of the electrical signal; and a transfer unit for transferring a patterned tactile signal to a user by means of the motion signal.

Abstract: A chip antenna includes a first ceramic substrate, a second ceramic substrate disposed to face the first ceramic substrate, a first patch disposed on the first ceramic substrate to operate as a feed patch, and a second patch disposed on the second ceramic substrate to operate as a radiation patch. One or both of the first ceramic substrate and the second ceramic substrate include a groove, and one or both of the first patch and the second patch is disposed in the groove of the respective first ceramic substrate and second ceramic substrate and protrudes from the groove.

Abstract: This application relates generally to certain substituted pyrrolizine compounds, and pharmaceutical compositions which inhibit HBV replication, and methods of making and using them.

Abstract: According to one embodiment, a tactile actuator can comprise: a housing having an accommodation space therein; a cap covering at least a portion of the accommodation space; a vibration unit disposed inside the accommodation space; an elastic member for connecting the housing and the vibration unit such that the vibration unit can vibrate with respect to the housing; a coil for forming a magnetic field to drive the vibration unit; and a control unit for determining any one driving mode on the basis of collected driving information from among a plurality of preset driving modes and determining, according to the driving mode, the characteristic of a current to be applied to the coil.

Abstract: A chip antenna includes a first substrate, a second substrate overlapping the first substrate, a first patch, provided on a first surface of the first substrate, operating as a feed patch, a second patch, provided on the second substrate, operating as a radiation patch, at least one feed via penetrating through the first substrate in a thickness direction and configured to provide a feed signal to the first patch, and a ground pad provided on the other surface of the first substrate. The first substrate comprises a ceramic sintered material. The ceramic sintered material comprises an Mg2SiO4 phase, an MgAl2O4 phase, and a CaTiO3 phase, and a content of the CaTiO3 phase in the ceramic sintered material ranges from 5.1 mol % to 15.1 mol %.

Abstract: An electronic device is provided such that a user can experience a quick launch of an application therein. The electronic device includes a housing, a display, an input unit, a processor, a non-volatile memory to store an application program, and a volatile memory to store instructions that allow the processor to load a first part of the application program in the volatile memory based on a first change of state of the electronic device, to load a second part of the application program in the volatile memory based on a second change of state of the electronic device and to display an image or text generated by the loaded first or second part. Since at least part of the application is preloaded before the second input is generated, only the remainder of the application has to be loaded in order to execute the application after the second input is generated.

Abstract: Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, Y1, Y2, or L are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

Abstract: The present disclosure relates to novel compounds for use in therapeutic treatment of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to processes and intermediates for the preparation of such compounds, methods of using such compounds and pharmaceutical compositions comprising the compounds described herein.

Abstract: Disclosed is a method and apparatus for generating a radar signal, in which performance of radar detection is ensured while increasing a spectrum efficiency in a radar network. The method comprises generating a set of frequency-modulation waveforms, generating an orthogonal code set, generating a set of coded frequency-modulation waveforms through element operation between the set of frequency-modulation waveforms and the orthogonal code set, calculating an objective function for the set of frequency-modulation waveforms with regard to a different set of coded frequency-modulation waveforms and previous sets of coded frequency-modulation waveforms, and selecting a current polyphase code set as an optimized polyphase code set when a result of current calculation is better or smaller than a result of previous iteration, and performing phase perturbation by replacing an element randomly selected in the current polyphase code set selected as the optimized polyphase code set with another admissible-phase element.

Abstract: A coil component includes a body having one surface and the other surface facing each other, and having one end surface and the other end surface facing each other in one direction; a supporting substrate embedded in the body; a coil portion disposed on the supporting substrate; a first lead-out portion connected to one end of the coil portion and exposed from the body; and a second lead-out portion connected to the other end of the coil portion and exposed from the body. The coil portion has a first pattern region facing the one surface and a second pattern region facing the other surface, each of the first and second pattern regions extends in the one direction, and a distance of the first pattern region in the one direction is shorter than a distance of the second pattern region in the one direction.

Abstract: Compounds for use in treating or preventing human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, L, W1, W2, X, Y, and Z are as defined herein. Methods associated with the preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.